Why you should attend
Pharmaceutical and biotech patent law is an important and rapidly changing practice area, and the program is designed to give you the information you need to maintain your practice edge, concentrating on new developments from 2012 and placing them in the context of constantly evolving areas of the law.
Technological innovation, Federal Circuit appellate oversight, and Supreme Court decisions continue to drive significant changes in the law. Several different perspectives on many of the most pressing issues will be offered from very experienced practitioners.
Do not miss this opportunity to fully understand the impact of new appellate decisions on your pharmaceutical and biotechnology patent practice.
What you will learn
- The PTO’s rules for implementing the new procedures of the America Invents Act
- Top pharmaceutical and biotech decisions from 2012
- Biosimilars: the approval process, data exclusivity and patent litigation
- Recent Supreme Court decisions and its continued focus on patent law
- Evolution of the Federal Circuit’s approach to claim construction and what it means in pharmaceutical and biotech cases
- Evolution of the Federal Circuit’s approach to claim construction and what it means in pharmaceutical and biotech cases
- An in-house counsel perspective on litigation of ANDA and biotech cases
- Biotech and Pharma licensing in Asia
Who should attend
Attorneys, whether in-house counsel or practicing at law firms, who are responsible for pharmaceutical and biotech patent prosecution, patent litigation, and patent transactions and strategies, will benefit from attending this program.
Morning Session: 9:00 a.m. - 12:30 p.m.
9:00 Program Overview
David K. Barr, Daniel L. Reisner
9:15 Claim Construction in Pharma/Biotech Cases
Hear the developments in the law of claim construction and consideration of specific claim construction issues that come up repeatedly in Pharma and Biotech cases.
Daniel L. Reisner
10:15 Strategic Planning for Biosimilar Approvals
Understand the intricacies of the biosimilar approval pathway and strategies for addressing exclusivity and patent issues.
David K. Barr, Betty Ryberg
11:15 Networking Break
11:30 Major 2012 Decisions in Pharma/Biotech
A review of the major Supreme Court, Federal Circuit and District Court decisions impacting pharmaceutical and biotech patents.
Stephen J. Elliott
12:30 Lunch Break
Afternoon session: 1:45 p.m. - 5:00 p.m.
1:45 Post-Grant Procedures under the America Invents Act
Learn the new procedures under the AIA for post-grant review, inter partes review, and supplemental examination and the advantages and potential pitfalls of each.
Joseph M. Drayton
2:45 Networking Break
3:00 Biotech and Pharma Licensing in Asia
This session will discuss the legal aspects of optimizing a patent portfolio by licensing in Japan, Taiwan and other Asian countries.
Dr. Judy Jarecki-Black, Grace L. Pan
4:00 In-House Panel on Pharma/Biotech Litigation
Obtain insight from in-house counsel of three major pharmaceutical companies on how to manage patent litigation in pharma and biotech.
Valeta Gregg, Ph.D., Donna M. Meuth, Thomas D. Smith
5:00 Adjourn
Co-Chair(s)
Speaker(s)
Valeta A Gregg, Ph.D. ~ Vice-President and Associate General Counsel, Intellectual Property, Regeneron Pharmaceuticals Inc
Donna M. Meuth ~ Senior Patent Counsel - Intellectual Property, Eisai Inc.
Betty Ryberg ~ Vice President, IP Litigation, Novartis Corporation
Thomas D. Smith ~ Assistant General Counsel (Patents), Global Litigation, G. S. K
Program Attorney(s)
John M. Mola ~ Director of California Operations, Practising Law Institute
New York City Seminar Location
PLI New York Center, 810 Seventh Avenue at 53rd Street (21st floor), New York, New York 10019. Message Center, program days only: (212) 824-5733.
New York City Hotel Accommodations
The New York Hilton & Towers1335 Avenue of the Americas, New York, NY 10019. 1 block from PLI Center. Reservations 1-800-HILTONS or, 1-877-NYC-HILT. Please mention that you are booking a room under the Practising Law Institute Corporate rate and the Client File # is 0495741. You can also
make reservations online to access Practising Law Institute rates.
The Warwick New York Hotel, 65 West 54th Street New York, NY 10019. 1 block from PLI Center. Reservations 800-223-4099 or, hotel direct 212-247-2700. Please mention that you are booking a room under the Practising Law Institute Corporate rate. Reservations on line at www.warwickhotelny.com Click reservations in menu bar on left. Select desired dates. In 'Special Rates' drop down window select Corporate Rate. In 'Rate Code' enter PLIN. Click search and select desired room type and rate plan. Or, you may email reservation requests to: res.ny@warwickhotels.com
Sheraton New York Hotel & Towers, 811 7th Avenue, New York, NY 10019, 1-800-325-3535 or (212) 581-1000. When calling, please mention Practising Law Institute and mention SET#311155. You may also book
online.
PLI's live programs are approved in all states that require mandatory continuing legal education for attorneys, except Arizona. Please be sure to check with your state for details.
Please check the CLE Calculator above each product description for CLE information specific to your state.
Special Note: In New York, newly admitted attorneys may receive CLE credit only for attendance at "transitional" programs during their first two years of admission to the Bar. Non-traditional course formats such as on-demand web programs or recorded items, are not acceptable for CLE credit. Experienced attorneys may choose to attend and receive CLE credit for either a transitional course or for one geared to experienced attorneys. All product types, including on-demand web programs and recorded items, are approved for experienced attorneys.
Please note: The State Bar of Arizona does not approve or accredit CLE activities for the Mandatory Continuing Legal Education requirement.
If you have already received credit for attending some or the entire program, please be aware that state administrators do not permit you to accrue additional credit for repeat viewing even if an additional credit certificate is subsequently issued.
Credit will be granted only to the individual on record as the purchaser unless alternative arrangements (prearranged groupcast) are made in advance.